Literature DB >> 25203319

DAISY: picking synthetic lethals from cancer genomes.

Colm J Ryan1, Christopher J Lord2, Alan Ashworth3.   

Abstract

A better understanding of genetic interactions in cancer might help identify new therapeutic approaches that exploit the concept of synthetic lethality. Ruppin and colleagues have developed a new computational method, DAISY, that predicts such interactions and potentially facilitates the delineation and validation of comprehensive genetic interaction networks.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2014        PMID： 25203319     DOI： 10.1016/j.ccr.2014.08.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  8 in total

1.  A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors.

Authors:  Malini Menon; Richard Elliott; Leandra Bowers; Nicolae Balan; Rumana Rafiq; Sara Costa-Cabral; Felix Munkonge; Ines Trinidade; Roderick Porter; Andrew D Campbell; Emma R Johnson; Christina Esdar; Hans-Peter Buchstaller; Birgitta Leuthner; Felix Rohdich; Richard Schneider; Owen Sansom; Dirk Wienke; Alan Ashworth; Christopher J Lord
Journal:  Sci Rep       Date:  2019-01-17       Impact factor: 4.379

2.  SynLethDB 2.0: a web-based knowledge graph database on synthetic lethality for novel anticancer drug discovery.

Authors:  Jie Wang; Min Wu; Xuhui Huang; Li Wang; Sophia Zhang; Hui Liu; Jie Zheng
Journal:  Database (Oxford)       Date:  2022-05-13       Impact factor: 4.462

3.  A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces.

Authors:  Eduard Porta-Pardo; Luz Garcia-Alonso; Thomas Hrabe; Joaquin Dopazo; Adam Godzik
Journal:  PLoS Comput Biol       Date:  2015-10-20       Impact factor: 4.475

4.  Moving ahead on harnessing synthetic lethality to fight cancer.

Authors:  Livnat Jerby-Arnon; Eytan Ruppin
Journal:  Mol Cell Oncol       Date:  2015-02-25

Review 5.  Synthetic lethality: emerging targets and opportunities in melanoma.

Authors:  Nicola Thompson; David J Adams; Marco Ranzani
Journal:  Pigment Cell Melanoma Res       Date:  2017-03-11       Impact factor: 4.693

6.  Identification of hyper-rewired genomic stress non-oncogene addiction genes across 15 cancer types.

Authors:  Jessica Xin Hjaltelin; Jose M G Izarzugaza; Lars Juhl Jensen; Francesco Russo; David Westergaard; Søren Brunak
Journal:  NPJ Syst Biol Appl       Date:  2019-08-07

7.  Literature-based translation from synthetic lethality screening into therapeutics targets: CD82 is a novel target for KRAS mutation in colon cancer.

Authors:  Hsih-Te Yang; Ming-Yu Chien; Jung-Hsien Chiang; Peng-Chan Lin
Journal:  Comput Struct Biotechnol J       Date:  2022-09-21       Impact factor: 6.155

8.  Integration of genome-level data to allow identification of subtype-specific vulnerability genes as novel therapeutic targets.

Authors:  Edward C Schwalbe; Lalchungnunga H; Fadhel Lafta; Timothy M Barrow; Gordon Strathdee
Journal:  Oncogene       Date:  2021-07-06       Impact factor: 9.867
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.